Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Iza Peszek"'
Autor:
Paul Chervinsky, Susan Lu, Kerstin Malmstrom, Ji Zhang, Iza Peszek, Michel Laviolette, Jean-Claude Pujet, Theodore F. Reiss
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 160:1862-1868
The primary objective of this study was to determine whether montelukast, an oral leukotriene receptor antagonist, provides additional clinical benefit to the effect of inhaled corticosteroids. A total of 642 patients with chronic asthma (FEV(1) 50 t
Autor:
M. Veselic-Charvat, M C Timmers, Jonathan A. Leff, Beth C. Seidenberg, M De Smet, Z. Diamant, P. J. Sterk, Diana C. Grootendorst, Aeilko H. Zwinderman, Iza Peszek
Publikováno v:
Clinical & Experimental Allergy. 29:42-51
Background Cysteinyl leukotrienes are capable of inducing chemotaxis of eosinophils in vitro and within the airways of animals and humans in vivo. Objective We hypothesized that montelukast (MK-0476), a potent cysLT1 receptor antagonist, would protec
Autor:
Andrew L. Rukhin, Iza Peszek
Publikováno v:
Journal of Statistical Planning and Inference. 41:281-290
The estimation problem of the hazard function on the basis of a lognormal (or normal) sample is considered from the decision theoretical point of view. A necessary and sufficient condition for the admissibility of a natural estimator under quadratic
Publikováno v:
Controlled clinical trials. 23(2)
Accuracy and repeatability of spirometry measurements are essential to obtain reliable efficacy data in randomized asthma clinical trials. We report our experience with a centralized spirometry quality assurance program that we implemented in our pha
Autor:
Iza Peszek, Andrew L. Rukhin
Publikováno v:
Statistics & Risk Modeling. 11
Autor:
Albert F. Finn, Beth C. Seidenberg, Alise S. Reicin, Iza Peszek, Richard H. White, Steven F. Weinstein, Lori Geissler, Ha Nguyen
Publikováno v:
Archives of Internal Medicine. 160:2481
Background Montelukast sodium, a potent, oral, specific leukotriene-receptor antagonist, has demonstrated clinical efficacy in the treatment of chronic asthma. Loratadine, a selective histamine type 1 (H 1 )-receptor antagonist, has demonstrated anti
Autor:
Iza Peszek, Alise Reicin
Publikováno v:
Controlled Clinical Trials. 19:S70